GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Enterprise Value

Blueprint Medicines (Blueprint Medicines) Enterprise Value

: $5,033.6 Mil (As of Today)
View and export this data going back to 2015. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Blueprint Medicines's Enterprise Value is $5,033.6 Mil. Blueprint Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-487.6 Mil. Therefore, Blueprint Medicines's EV-to-EBIT ratio for today is -10.32.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Blueprint Medicines's Enterprise Value is $5,033.6 Mil. Blueprint Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-475.9 Mil. Therefore, Blueprint Medicines's EV-to-EBITDA ratio for today is -10.58.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Blueprint Medicines's Enterprise Value is $5,033.6 Mil. Blueprint Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $249.4 Mil. Therefore, Blueprint Medicines's EV-to-Revenue ratio for today is 20.18.


Blueprint Medicines Enterprise Value Historical Data

The historical data trend for Blueprint Medicines's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,559.59 5,699.30 5,968.90 1,924.26 5,262.07

Blueprint Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,924.26 2,136.31 3,348.05 2,671.44 5,262.07

Competitive Comparison

For the Biotechnology subindustry, Blueprint Medicines's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Enterprise Value falls into.



Blueprint Medicines Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Blueprint Medicines's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Blueprint Medicines's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blueprint Medicines  (NAS:BPMC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Blueprint Medicines's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5033.566/-487.61
=-10.32

Blueprint Medicines's current Enterprise Value is $5,033.6 Mil.
Blueprint Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-487.6 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Blueprint Medicines's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=5033.566/-475.945
=-10.58

Blueprint Medicines's current Enterprise Value is $5,033.6 Mil.
Blueprint Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-475.9 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Blueprint Medicines's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5033.566/249.38
=20.18

Blueprint Medicines's current Enterprise Value is $5,033.6 Mil.
Blueprint Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $249.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blueprint Medicines Enterprise Value Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (Blueprint Medicines) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Executives
Ariel Hurley officer: Principal Accounting Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers director, officer: CEO & President BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray officer: SVP, Technical Operations C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni officer: President, R and D 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes officer: Chief Medical Officer C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter officer: Chief Scientific Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee officer: Chief Commercial Officer C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi officer: Chief Commercial Officer 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain officer: EVP and Chief Legal Officer C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel officer: Principal FAO BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus officer: Chief People Officer C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland officer: Chief Business Officer BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai director BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142